Skip to content

Intellia Therapeutics

US · NTLA #2899 by market cap Listed 2016
11.71 -0.66 -5.34%
Live - 5344 symbols - heartbeat 337s ago · 2026-10-08 08:30
Pre-market 11.66 -0.43%
After-hours 11.81 +0.85%
Overnight 11.68 -0.26%
Market cap
1.64B
P/B
2.25
EPS
-3.81
Reader sentiment Are you bullish or bearish on NTLA?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Morgan Stanley Maintains Intellia Therapeutics(NTLA.US) With Hold Rating, Maintains Target Price $15
    Market Newswire · 2026/8/10
  • Rating change
    J.P. Morgan Maintains Intellia Therapeutics(NTLA.US) With Sell Rating, Announces Target Price $8
    Market Newswire · 2026/5/14
  • Rating change
    Goldman Sachs Maintains Intellia Therapeutics(NTLA.US) With Sell Rating, Maintains Target Price $9
    Market Newswire · 2026/8/7
  • Tracking Cathie Wood: Added over 110,000 shares of gene-editing firm NTLA, while continuing to reduce holdings and optimize portfolio allocation.
    牛牛名人追蹤 · 2026/9/14
  • H.C. Wainwright Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $25
    Market Newswire · 2026/9/9
  • Rating change
    Analysts Have Conflicting Sentiments on These Healthcare Companies: Intellia Therapeutics (NTLA), TriSalus Life Sciences (TLSI) and Fractyl Health, Inc. (GUTS)
    TipRanks · 2026/5/13
  • Rating change
    William Blair Maintains Intellia Therapeutics(NTLA.US) With Buy Rating
    Market Newswire · 2026/6/15
  • Rating change
    J.P. Morgan Remains a Sell on Intellia Therapeutics (NTLA)
    TipRanks · 2026/5/14
  • Rating change
    A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $9 to $58
    Market Newswire · 2026/4/29
  • Rating change
    A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $19 to $49
    Market Newswire · 2026/6/16
  • Rating change
    TD Cowen Maintains Intellia Therapeutics(NTLA.US) With Buy Rating
    Market Newswire · 2026/6/15
  • Rating change
    A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $15 to $49
    Market Newswire · 2026/5/12
  • Rating change
    Evercore Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $24
    Market Newswire · 2026/8/7
  • Rating change
    BofA Securities Maintains Intellia Therapeutics(NTLA.US) With Hold Rating, Cuts Target Price to $17
    Market Newswire · 2026/8/8
  • JonesTrading Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $29
    Market Newswire · 2026/8/15
  • Rating change
    Analysts Are Bullish on Top Healthcare Stocks: Intellia Therapeutics (NTLA), Sagimet Biosciences, Inc. Class A (SGMT)
    TipRanks · 2026/4/28
  • Rating change
    CCORF Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $49
    Market Newswire · 2026/8/8
  • Rating change
    Wolfe Research Downgrades Intellia Therapeutics(NTLA.US) to Sell Rating, Announces Target Price $9
    Market Newswire · 2026/7/16
  • Wedbush Initiates Intellia Therapeutics(NTLA.US) With Hold Rating, Announces Target Price $13
    Market Newswire · 2026/9/9
  • Rating change
    A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $15 to $25
    Market Newswire · 2026/8/7

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 08:30:29 · For reference only, not investment advice and not tailored to your situation.